In in vitro studies, a synthetic small peptide inhibitor of TGF-β, P17, was shown to inhibit the suppressive activities of Treg cells on effector T cells (165), indicating the potential for P17 to be used to enhance protective effector T cell responses in vivo during infection. The gene discussed is TGFB1; the disease is infection.